OMVOH (Eli Lilly Australia Pty Ltd)
Product name
OMVOH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
153 (255 working days)
Active ingredients
mirikizumab
Registration type
EOI
Indication
OMVOH is now also indicated for the treatment of moderately to severely active Crohn’s disease (CD) in adult patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy or a biological medicine, or have medical contraindications to such therapies.